EVO
Price
$3.50
Change
-$0.01 (-0.28%)
Updated
Aug 29, 04:59 PM (EDT)
Capitalization
1.23B
68 days until earnings call
EVOK
Price
$5.55
Change
+$0.26 (+4.91%)
Updated
Aug 29, 03:53 PM (EDT)
Capitalization
8.24M
Interact to see
Advertisement

EVO vs EVOK

Header iconEVO vs EVOK Comparison
Open Charts EVO vs EVOKBanner chart's image
Evotec SE
Price$3.50
Change-$0.01 (-0.28%)
Volume$2.04K
Capitalization1.23B
Evoke Pharma
Price$5.55
Change+$0.26 (+4.91%)
Volume$100
Capitalization8.24M
EVO vs EVOK Comparison Chart in %
Loading...
EVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EVOK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EVO vs. EVOK commentary
Aug 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EVO is a Buy and EVOK is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 29, 2025
Stock price -- (EVO: $3.51 vs. EVOK: $5.29)
Brand notoriety: EVO and EVOK are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: EVO: 40% vs. EVOK: 1%
Market capitalization -- EVO: $1.23B vs. EVOK: $8.24M
EVO [@Pharmaceuticals: Generic] is valued at $1.23B. EVOK’s [@Pharmaceuticals: Generic] market capitalization is $8.24M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.6B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EVO’s FA Score shows that 0 FA rating(s) are green whileEVOK’s FA Score has 0 green FA rating(s).

  • EVO’s FA Score: 0 green, 5 red.
  • EVOK’s FA Score: 0 green, 5 red.
According to our system of comparison, EVOK is a better buy in the long-term than EVO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EVO’s TA Score shows that 4 TA indicator(s) are bullish while EVOK’s TA Score has 5 bullish TA indicator(s).

  • EVO’s TA Score: 4 bullish, 6 bearish.
  • EVOK’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, EVOK is a better buy in the short-term than EVO.

Price Growth

EVO (@Pharmaceuticals: Generic) experienced а -0.85% price change this week, while EVOK (@Pharmaceuticals: Generic) price change was -16.56% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.25%. For the same industry, the average monthly price growth was +68.20%, and the average quarterly price growth was +81.63%.

Reported Earning Dates

EVO is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.25% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EVO($1.23B) has a higher market cap than EVOK($8.24M). EVOK YTD gains are higher at: 19.683 vs. EVO (-15.625). EVOK has higher annual earnings (EBITDA): -4.88M vs. EVO (-121.33M). EVO has more cash in the bank: 356M vs. EVOK (12.1M). EVOK has less debt than EVO: EVOK (5.13M) vs EVO (107M). EVO has higher revenues than EVOK: EVO (777M) vs EVOK (12.8M).
EVOEVOKEVO / EVOK
Capitalization1.23B8.24M14,884%
EBITDA-121.33M-4.88M2,485%
Gain YTD-15.62519.683-79%
P/E RatioN/A0.04-
Revenue777M12.8M6,070%
Total Cash356M12.1M2,942%
Total Debt107M5.13M2,086%
FUNDAMENTALS RATINGS
EVO vs EVOK: Fundamental Ratings
EVO
EVOK
OUTLOOK RATING
1..100
5936
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
47
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
8339
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EVOK's Valuation (47) in the Pharmaceuticals Other industry is somewhat better than the same rating for EVO (93) in the null industry. This means that EVOK’s stock grew somewhat faster than EVO’s over the last 12 months.

EVOK's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as EVO (100) in the null industry. This means that EVOK’s stock grew similarly to EVO’s over the last 12 months.

EVOK's SMR Rating (100) in the Pharmaceuticals Other industry is in the same range as EVO (100) in the null industry. This means that EVOK’s stock grew similarly to EVO’s over the last 12 months.

EVOK's Price Growth Rating (39) in the Pharmaceuticals Other industry is somewhat better than the same rating for EVO (83) in the null industry. This means that EVOK’s stock grew somewhat faster than EVO’s over the last 12 months.

EVOK's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as EVO (100) in the null industry. This means that EVOK’s stock grew similarly to EVO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EVOEVOK
RSI
ODDS (%)
Bullish Trend 2 days ago
69%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
71%
Bullish Trend 2 days ago
85%
Momentum
ODDS (%)
Bearish Trend 2 days ago
76%
Bullish Trend 2 days ago
86%
MACD
ODDS (%)
Bearish Trend 2 days ago
73%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
73%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
73%
Bullish Trend 2 days ago
74%
Advances
ODDS (%)
Bullish Trend 22 days ago
69%
Bullish Trend 3 days ago
79%
Declines
ODDS (%)
Bearish Trend 4 days ago
79%
Bearish Trend 5 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
89%
Aroon
ODDS (%)
Bearish Trend 2 days ago
67%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
EVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EVOK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PRVA21.810.06
+0.28%
Privia Health Group
NWS34.05-0.06
-0.18%
News Corp
CLMB124.27-0.48
-0.38%
Climb Global Solutions
SPAI6.82-0.09
-1.30%
Safe Pro Group Inc
MASK0.64-0.01
-1.54%
3 E Network Technology Group Limited

EVOK and

Correlation & Price change

A.I.dvisor tells us that EVOK and RMTI have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EVOK and RMTI's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EVOK
1D Price
Change %
EVOK100%
-3.64%
RMTI - EVOK
31%
Poorly correlated
+22.45%
NBIX - EVOK
28%
Poorly correlated
+0.59%
EOLS - EVOK
26%
Poorly correlated
-0.79%
EVO - EVOK
24%
Poorly correlated
+0.57%
PRFX - EVOK
24%
Poorly correlated
-8.70%
More